The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and biomarkers associated with risk for Crohn's disease in unaffected first-degree relatives of patients with inflammatory bowel disease. We hypothesize that personalized risk disclosure via the PRE-Crohn's educational tool is both feasible and successful in modifying behaviors associated with Crohn's disease risk and normalizing pre-clinical disease biomarkers when compared to standard Crohn's disease education. Broadly, completion of this project will also help elucidate the role of lifestyle and dietary factors in pre-clinical Crohn's disease development in high-risk individuals, and provide novel insight into potential strategies for disease prevention in this population.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
80
We will develop a web-based, personalized risk estimation for CD (PRE-Crohn's) tool to quantitate participants' relative risk (RR) and lifetime risk of CD based on known risk factors for disease. We will consider the following risk factors for Crohn's disease: body mass index (BMI); smoking history; NSAID use; intake of fruit, fiber, and added sugar; oral contraceptive use (females); antibiotic use; breast-feeding; pets in home; and anti-microbial biomarker positivity. This tool will also display a participants' personalized summary of their risk factors for CD as well as educational tools for modifying these factors. Construction of this tool is based on the Your Disease Risk tool developed by the Siteman Cancer Center at Washington University in St. Louis School of Medicine. The interventional group will also receive standard education about Crohn's disease (comparison group intervention) via the web-based tool.
The comparison group will receive standard education about Crohn's disease, which will include information regarding the prevalence of disease, clinical presentation including signs and symptoms of disease, and treatment options including available medications. Upon completion of the study, the comparator arm will be given the option of receiving their personalized risk of Crohn's disease with the PRE-Crohn's tool as well.
Massachusetts General Hospital
Boston, Massachusetts, United States
RECRUITINGTotal enrollment (n) at 1.5 years and retention rate (%) at study conclusion
The total enrollment at 1.5 years and the retention rate recorded at the conclusion of the study will be measured based on completion of the 6-month survey.
Time frame: 1.5 years and time of study completion
Motivation to change smoking behavior
We will measure change in contemplation ladder scores for motivation to change smoking behavior (yes/no for achieving a 1-point increase)
Time frame: 8 weeks and 6 months
Motivation to change diet
We will measure change in contemplation ladder scores for motivation to change diet (yes/no for achieving a 1-point increase)
Time frame: 8 weeks and 6 months
Motivation to change physical activity
We will measure change in contemplation ladder scores for motivation to change physical activity (yes/no for achieving a 1-point increase)
Time frame: 8 weeks and 6 months
Change in physical activity
We will measure change in physical activity (MET-hours/week)
Time frame: 8 weeks and 6 months
Change in fruit intake
We will measure change in fruit intake (servings/day)
Time frame: 8 weeks and 6 months
Change in vegetable intake
We will measure change in vegetable intake (servings/day)
Time frame: 8 weeks and 6 months
Change in processed meat intake
We will measure change in processed meat intake (servings/day)
Time frame: 8 weeks and 6 months
Change in fiber intake
We will measure change in fiber intake (grams/day)
Time frame: 8 weeks and 6 months
Change in added sugar intake
We will measure change in added sugar intake (grams/day)
Time frame: 8 weeks and 6 months
Change in smoking behaviors
We will measure change in smoking behaviors including current smoking vs non-smoking and cigarettes/day
Time frame: 8 weeks and 6 months
Change in C-reactive protein (CRP; mg/L)
We will measure change in CRP (mg/L)
Time frame: 8 weeks and 6 months
Change in fecal calprotectin (mcg/g)
We will measure change in fecal calprotectin (mcg/g)
Time frame: 8 weeks and 6 months
Change in seropositivity for antimicrobial biomarkers
We will measure several Crohn's disease associated antimicrobial biomarkers including ASCA IgA and IgG, anti-OmpC, anti-CBir1, anti-A4-Fla2 and anti-FlaX will be assayed using the PROMETHEUS® IBD sgi Diagnostic® panel. Positivity for each of these components are defined as follows: ASCA IgA \> 9.2 EU/mL; ASCA IgG \> 11.9 EU/mL; anti-OmpC \> 11.3 EU/mL; anti-CBir1 \> 35.4 EU/mL; anti-A4-Fla2 \> 32.4 EU/mL and anti-FlaX \> 36.0 EU/mL. Total biomarker positivity (secondary outcome) will be defined as the presence of 1 or more positive individual biomarkers above. We will then assess for change in total biomarker positivity at 8 weeks and 6 months compared to baseline.
Time frame: 8 weeks and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.